[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anticoagulant-drugs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anticoagulant-drugs":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100608987","effect-of-oral-antiplatelet-or-anticoagulant-drugs-on-postoperative-bleeding-risk-and-venous-closure-rate-in-patients-with-lower-extremity-varicose-veins-after-radiofrequency-ablation-100608987",false,"NCT07208695","Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","Inclusion Criteria:\n\n* Aged 18 years or older, with a confirmed diagnosis of primary lower extremity varicose veins (CEAP classification C2-C6) based on clinical examination and duplex ultrasound.\n* Underwent endovenous radiofrequency ablation (RFA) of the great saphenous vein as the primary intervention.\n* Postoperatively, either: (a) continuously uses standard-dose oral antiplatelet drugs (e.g., aspirin 100mg\u002Fday, clopidogrel 75mg\u002Fday) or oral anticoagulant drugs (e.g., warfarin with INR maintained at 2.0-3.0, direct oral anticoagulants at standard therapeutic doses) as per clinical routine, or (b) does not use any antithrombotic drugs.\n* Able to understand and comply with the follow-up schedule (including 30-day bleeding assessment and 6-month duplex ultrasound examination) and provide informed consent.\n\nExclusion Criteria:\n\n* Presence of secondary varicose veins caused by deep vein thrombosis, venous malformation, or other vascular disorders.\n* History of coagulation disorders (e.g., hemophilia, thrombocytopenia with platelet count \\\u003C100×10⁹\u002FL) or use of other antithrombotic agents (e.g., low-molecular-weight heparin, glycoprotein IIb\u002FIIIa inhibitors) postoperatively.\n* Major bleeding events (e.g., gastrointestinal bleeding, intracranial hemorrhage) within 3 months prior to RFA.\n* Severe hepatic insufficiency (Child-Pugh class C), renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), or other life-threatening systemic diseases.\n* Unable to complete follow-up due to mental disorders, mobility limitations, or other reasons, or refusal to sign the informed consent form.","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","OBSERVATIONAL","This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation. Its main objectives are to determine the impact of these medications on postoperative 30-day bleeding risk and postoperative 3-month venous closure rate in this patient population. Researchers will compare three groups-patients receiving oral antiplatelet drugs, those receiving oral anticoagulant drugs, and those not receiving either type of drug-to identify differences in the two key outcomes. Participants will complete baseline data collection (including medical history, medication use, and lower extremity venous assessment) before or shortly after radiofrequency ablation, undergo 30-day postoperative follow-up to evaluate bleeding events (such as minor bleeding or major bleeding requiring medical intervention), receive venous ultrasound at 3 months postoperatively to measure venous closure rate, and report any medication changes or adverse events during the follow-up period.",[23,24,25,26],"Oral Antiplatele","Anticoagulant Drugs","Lower Extremity Varicose Veins","Radiofrequency Ablation","NOT_YET_RECRUITING","2025-09-28",{"date":30,"type":31},"2025-10-06","ACTUAL",{"date":33,"type":19},"2025-10-01",{"date":35,"type":19},"2026-06-01",{"name":37,"class":38},"Chengdu University of Traditional Chinese Medicine","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":16,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":49,"conditions":50,"keywords":55,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100592454","pharmacometrics-analysis-of-rivaroxaban-in-chinese-children-aged-over-2-years-100592454","NCT06993636","Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years","Population Pharmacokinetic\u002FPharmacodynamic Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years With Giant Coronary Artery Aneurysm After Kawasaki Disease","Inclusion Criteria:\n\n1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;\n2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 6 months;\n3. Children aged 2 years to \\\u003C18 years\n\nExclusion Criteria:\n\n1. Active bleeding or bleeding risk contraindicating anticoagulant therapy\n2. Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment\n3. Patients participating in clinical trials of other drugs at the same time","2 Years",{"count":48,"type":19},60,"Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after Kawasaki disease who received rivaroxaban treatment. Rivaroxaban plasma concentrations, anti-factor Xa activity levels, and genetic polymorphisms will be measured and analyzed to support the population pharmacokinetic\u002Fpharmacodynamic analysis",[51,52,53,24,54],"Kawasaki Disease","Coronary Artery Aneurysm","Rivaroxaban","Pharmacokinetics and Pharmacodynamics",[56,57,58,59,60],"Kawasaki disease","Coronary artery aneurysm","Population pharmacokinetic and pharmacodynamic","rivaroxaban","anticoagulant","RECRUITING","2025-05-25",{"date":64,"type":31},"2025-05-29",{"date":66,"type":31},"2023-01-01",{"date":68,"type":19},"2026-12-31",{"name":70,"class":38},"Children's Hospital of Fudan University",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":71},"100588922","safety-and-efficacy-of-edoxaban-and-rivaroxaban-to-cerebral-venous-thrombosis-in-chinese-patients-100588922","NCT06947707","Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients","Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Patient aged from 18 to 80 years and no gender preference;\n2. Diagnosis of CVT as confirmed on MRBTI\u002FMRV or CT\u002FCTV or DSA;\n3. Acute or subacute CVT from onset to door within 4 weeks;\n4. The treating clinician irrelevant to the study is of the opinion that the patient is appropriate for edoxaban or rivaroxaban;\n5. Patient or legally authorized representative is able to give written informed consent.\n\nExclusion Criteria:\n\n1. Patient refuse to take edoxaban or rivaroxaban to treat CVT;\n2. Pregnancy or breastfeeding women at the time of enrollment, or women who plan to get pregnant during study;\n3. Patient is anticipated to require invasive procedure (e.g. thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation;\n4. CVT secondary to central nervous system infection or severe head trauma;\n5. It is in the proliferative stage of malignant tumors currently or within 6 months of diagnosis;\n6. Bleeding diathesis or other contraindication to anticoagulation;\n7. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use;\n8. Concomitant use of strong CYP3A4 or P-gp inhibitors;\n9. Impaired renal function (CrCl\\\u003C30 mL\u002Fmin using Cockcroft-Gault equation) or investigator anticipate the CrCl lower than 30 mL\u002Fmin during study;\n10. Impaired liver function (ALT or AST exceeds twice the normal upper limit) or diagnosed as acute hepatitis currently;\n11. Patient is unable to swallow due to depressed level of consciousness or other reasons;\n12. Patient has a severe or fatal comorbid illness with life expectancy less than 6 months;\n13. Patient with severe hypertension (SBP≥180mmHg and\u002For DBP≥110mmHg);\n14. Patient is known to be allergic to edoxaban or rivaroxaban.","80 Years",{"count":81,"type":19},1486,"The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous thrombosis (CVT). The main question it aims to answer are:\n\n* Do cerebral veins or venous sinuses recanalize during the treatment period of edoxaban and rivaroxaban?\n* Do the bleeding events occur during the treatment period of edoxaban and rivaroxaban?\n\nThe main tasks participants will be asked to do:\n\n* Participants will comply fully with the prescribed regimen and take the edoxaban or rivaroxaban as directed at the specified dosage.\n* Participants will return to hospital for scheduled follow-up assessments at months 3, 6, 9, and 12 post-enrollment to undergo face-to-face visits with investigators.",[84,85,86,87,24,88,89,90,91],"Cerebral Venous Thrombosis","Anticoagulants and Thrombotic Disorders","Anticoagulation Treatment","Anticoagulant Therapy","NOACs","Anticoagulant Prophylaxis\u002FTherapy","Anticoagulation With NOAC","Anticoagulation With Direct Oral Anticoagulants","2025-04-20",{"date":94,"type":31},"2025-04-27",{"date":96,"type":31},"2025-04-10",{"date":98,"type":19},"2027-12-31",{"name":100,"class":38},"Xuanwu Hospital, Beijing"]